# Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB)

> **NCT05534750** · PHASE2 · RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 60 (estimated)

## Conditions studied

- Tuberculosis
- Multidrug Resistant Tuberculosis

## Interventions

- **DRUG:** Tedizolid arm (SIVEXTRO®)
- **DRUG:** Linezolid arm (ZYVOXID®)
- **DRUG:** Standard quadruple therapy arm

## Key facts

- **NCT ID:** NCT05534750
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-20
- **Primary completion:** 2026-04
- **Final completion:** 2026-05
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05534750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05534750, "Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB)". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT05534750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*